Here, we show that ATR inhibitors exhibit antitumor activity against preclinical models of ARMS and that PAX3-FOXO1 is sufficient to increase sensitivity to ATR inhibition. This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.